Simulations Plus Inc (SLP) 7.71 $SLP Simulations Plus

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Simulations Plus Inc (SLP) 7.71 $SLP

Simulations Plus Shares Down 23.0% Since SmarTrend's Sell Call (SLP)
Comtex SmarTrend(R) - Mon Jun 27, 1:18PM CDT
SmarTrend identified a Downtrend for Simulations Plus (NASDAQ:SLP) on February 8th, 2016 at $8.93. In approximately 5 months, Simulations Plus has returned 23.00% as of today's recent price of $6.88.
SLP: 7.71 (+0.18)

Simulations Plus Reports Preliminary Revenues for Third Quarter FY2016
BusinessWire - Tue Jun 07, 7:30AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for the third quarter of its fiscal year 2016, the period ended May 31, 2016 (3QFY16).
SLP: 7.71 (+0.18)

Simulations Plus to Present at LD Micro Invitational on June 7, 2016
BusinessWire - Thu Jun 02, 7:30AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all phases of pharmaceutical discovery and development, announced that Walt Woltosz, chief executive officer, will present at the 6th Annual LD Micro Invitational investor conference on Tuesday, June 7, 2016, at 11:30 a.m. PT. The conference will be held June 7-9, 2016, at the Luxe Sunset Bel Air Hotel in Los Angeles.
SLP: 7.71 (+0.18)

Simulations Plus (SLP): Moving Average Crossover Alert
Zacks Equity Research - Zacks Investment Research - Mon May 09, 9:12AM CDT
Simulations Plus, Inc. (SLP) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
SLP: 7.71 (+0.18)

Simulations Plus Announces Quarterly Cash Dividend of $0.05 Per Share
BusinessWire - Fri Apr 22, 7:30AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.05 per share to its shareholders. This cash dividend will be distributed on Monday, May 9, 2016, to shareholders of record as of Monday, May 2, 2016.
SLP: 7.71 (+0.18)

Simulations Plus Releases DDDPlus Version 5.0
BusinessWire - Thu Apr 14, 7:30AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that it has released Version 5.0 of its DDDPlus(TM) in vitro dissolution experiment simulation software.
SLP: 7.71 (+0.18)

Simulations Plus posts 2Q profit
Automated Insights - Wed Apr 13, 3:06PM CDT
LANCASTER, Calif. (AP) _ Simulations Plus Inc. (SLP) on Wednesday reported fiscal second-quarter profit of $1.1 million.
SLP: 7.71 (+0.18)

Simulations Plus Reports Second Quarter FY2016 Financial Results
BusinessWire - Wed Apr 13, 3:01PM CDT
Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all phases of pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today reported financial results for its second quarter of fiscal year 2016, the period ended February 29, 2016 (2QFY16).
SLP: 7.71 (+0.18)

Simulations Plus Releases KIWI Version 1.5
BusinessWire - Tue Mar 15, 2:00PM CDT
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its Buffalo division (Cognigen Corporation) has released Version 1.5 of KIWI(TM), a private cloud-based platform to efficiently and consistently organize, process, evaluate, and communicate modeling and simulation results.
SLP: 7.71 (+0.18)

Simulations Plus Reports Record Preliminary Revenues for Second Quarter FY2016
BusinessWire - Thu Mar 10, 7:30AM CST
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for the second quarter of its fiscal year 2016, the period ended February 29, 2016 (2QFY16).
SLP: 7.71 (+0.18)

Simulations Plus (SLP): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 7:37AM CST
Simulations Plus is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective
SLP: 7.71 (+0.18)

Shares of SLP Up 17.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Feb 01, 5:21PM CST
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on December 29th, 2015 at $9.62. In approximately 1 month, Simulations Plus has returned 17.42% as of today's recent price of $11.29.
SLP: 7.71 (+0.18)

Simulations Plus to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
BusinessWire - Tue Jan 26, 7:30AM CST
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today that Walt Woltosz, Chairman and Chief Executive Officer, will provide a company overview at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on Thursday, February 11, 2016, at 8:30 a.m. EST. The conference will be held at the Convene Conference Center at 730 Third Avenue in New York City. Simulations Plus management will be available during the day for one-on-one meetings.
SLP: 7.71 (+0.18)

Uptrend Call Working As Simulations Plus Stock Rises 17.6% (SLP)
Comtex SmarTrend(R) - Mon Jan 25, 12:02PM CST
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on December 29th, 2015 at $9.62. In approximately 4 weeks, Simulations Plus has returned 17.63% as of today's recent price of $11.31.
SLP: 7.71 (+0.18)

Simulations Plus Reports First Quarter FY2016 Financial Results
BusinessWire - Thu Jan 14, 3:01PM CST
Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all phases of pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today reported financial results for its first quarter of fiscal year 2016, the period ended November 30, 2015 (1QFY16).
SLP: 7.71 (+0.18)

New Information Reveals Opportunity in Volatility - Featured Research on Simulations Plus, Olympic Steel, Unity Bancorp, and Shore Bancshares
ACCESSWIRE - Mon Jan 11, 7:20AM CST
NEW YORK, NY / ACCESSWIRE / January 11, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Simulations Plus Inc. (NASDAQ: SLP), Olympic Steel Inc. (NASDAQ: ZEUS), Unity Bancorp Inc. (NASDAQ: UNTY) and Shore Bancshares Inc. (NASDAQ: SHBI). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
SLP: 7.71 (+0.18), SHBI: 11.70 (+0.01), ZEUS: 28.74 (+0.82), UNTY: 12.99 (+0.18)

Simulations Plus Sets Date for 1st Quarter 2016 Earnings Release and Conference Call
BusinessWire - Fri Jan 08, 12:42PM CST
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of software and consulting services for pharmaceutical R&D and environmental toxicology, announced that it expects to file its quarterly report on Form 10-Q for the first quarter of its 2016 fiscal year, ending November 30, 2015, with the U.S. Securities and Exchange Commission on Thursday, January 14, 2016. Dr. Ted Grasela, president, and Walt Woltosz, chairman and CEO, will host a conference call to discuss the Company's performance on January 14, 2016, at 1:15 p.m. PST / 4:15 p.m. EST.
SLP: 7.71 (+0.18)

Simulations Plus to Present at Two Upcoming Investor Conferences
BusinessWire - Tue Nov 24, 7:30AM CST
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of software for pharmaceutical discovery and development, today announced that John DiBella ,Vice President of Marketing and Sales, will present at the LD Micro Conference at 9:00 a.m. PST, Track 5, on Wednesday, December 2, 2015. The conference will be held December 1-3, 2015 at the Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard in Los Angeles. The Company's group presentation will be available for the public to access at http://wsw.com/webcast/ldmicro9/slp. This webcast will be archived for 90 days following the live presentation. Simulations Plus management will be available during the day on Dec. 2, for one-on-one meetings. Please contact LD Micro to schedule a meeting.
SLP: 7.71 (+0.18)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hansa's Idefirix Shows Promise for Kidney Transplants

Updated Category News Views 11

Compelling Progress from Hansa Biopharma Y'know, navigating through the biotech jungle isn't for the faint-hearted. Hansa Biopharma's recent results with Idefirix could just be the beacon of hope for patients struggling on transplant lists. Announced at the ASN Kidney Week—a name that's got weight, by the way—these findings aren't just filling space. They're promising...

Continue Reading
Concierge Hybrid Choice™: Transforming Patient Care

Updated Category News Views 22

A New Way to Nurture Patient Relationships This isn't just another cookie-cutter patient care program rolling out—it’s a genuine shake-up in the way doctors connect with their patients. Rishika Kaundal, MD, a dedicated family medicine physician, is pioneering change in Midlothian, Virginia with her Hybrid Choice™ concierge program. This isn't a fluff piece; it's a...

Continue Reading
Dimethylaminopropylamine Market Eyes $732M by 2035

Updated Category News Views 21

Surfactants and Epoxy Fuel Dimethylaminopropylamine Demand Hot off the presses, folks! Dimethylaminopropylamine, or DMAPA if you're into acronyms, is gearing up for a steady climb to a $731.9 million market value by the year 2035. That's quite the leap from the $452.6 million we saw back in 2025. According to Credence Research's latest estimates, this amine is hitching...

Continue Reading
BOB Raises $5.5M for AI Banking Platform Revolution

Updated Category News Views 24

Cracking the Code of Small Business Finance BOB, a Miami hotshot aiming to be more than just another fintech flash in the pan, has wrangled a sweet $5.5 million in seed capital. They're shaking hands with big names like Peter Thiel and the mastermind behind Plaid, Zak Perret, through Mischief Ventures. The plan? To build an AI-powered finance savior for small businesses...

Continue Reading
First Citizens Surprises with Q3 Gains and Buyback Plan

Updated Category News Views 5

Unexpected Third Quarter Tailwinds for First Citizens There are days in this trading gig when a bank I'll barely sneeze at hits out of the park. First Citizens BancShares (NASDAQ:FCNCA) pulled off such a feat, wringing out a third-quarter 2026 performance that beat their own benchmarks. They threw $600 million back to shareholders in repurchased stocks while repaying an...

Continue Reading
Blockchain Boom: Media Market to Hit $3.33B by 2035

Updated Category News Views 35

Blockchain is Not Just for Bitcoin Anymore Who would've thought, right? Blockchain's no longer just the playground for cryptocurrency enthusiasts. Today, it's making waves in the media and entertainment sector. Latest numbers from Credence Research have this market set to explode from $748 million in 2025 to a jaw-dropping $3.33 billion by 2035. Yeah, folks, that's a...

Continue Reading
Concrete Admixtures Market: A Billion-Dollar Boom

Updated Category News Views 24

A Look Under the Hood of Concrete Admixtures It's a concrete jungle out there, folks—literally. The once overlooked market of concrete admixtures is gearing up for quite the makeover, projected to hit USD 35.87 billion by 2035. For those of you tuning in, we're talking about chemicals that mix into your average concrete to change its properties. And, believe it or not,...

Continue Reading
Estrogen Patch Struggles: Menopause Care Needs a Boost

Updated Category News Views 25

Troublesome Estrogen Patch Shortages Hit Hard You'd think getting a prescription filled would be a simple task, right? Well, think again. Midi Health shines a glaring light on how the supposed ease of getting hormone therapy is anything but for many women in 2026. Out of those scrambling for estradiol patches, 44% hit roadblocks in pharmacies, and a third hit an all-out...

Continue Reading
CardVault by Tom Brady Expands to Pittsburgh

Updated Category News Views 4

Tom Brady’s CardVault Hits Pittsburgh’s Historic Strip District Pittsburgh just got another feather in its cap with CardVault by Tom Brady marking its 20th store at The Terminal. As if this city needed more sports excitement! Pittsburgh, with its die-hard Steelers, Penguins, and Pirates fans, snags a premium spot for sports collectibles. A Prime Spot for Serious...

Continue Reading
Stephen A. Smith Calls for Corporate Support of HBCUs

Updated Category News Views 4

A Stand for Education at the White House Stephen A. Smith stirred the pot with his decision to attend a White House dinner, a move that had tongues wagging across the media landscape. But this time, it wasn't about the usual hustle and bustle of the sports world. Smith had his sights set on the big picture, specifically, the long-term financial stability of Historically...

Continue Reading

Top 5 Most Recently Viewed Articles

Hyzon Secures Major Order for Hydrogen Fuel Cell Trucks

Updated Category News Views 90

Hyzon Receives Order for Hydrogen Fuel Cell Electric Trucks Hyzon, an innovator in hydrogen fuel cell systems, has announced an exciting new order for two Fuel Cell Electric Trucks (FCETs). This marks a significant step for the company as it continues to provide sustainable solutions for refuse collection through advanced technology. The order comes from a reputable...

Continue Reading
Heron Therapeutics Reports Impressive Financial Gains for 2024

Updated Category News Views 362

Heron Therapeutics Achieves Remarkable Financial Results Heron Therapeutics, Inc. (Nasdaq: HRTX) has announced its outstanding financial performance for 2024, showcasing impressive results that highlight the company's strategic advancements within the biotechnology sector. The company reported a Q4 2024 GAAP net income of $3.6 million, leading to a profitable year-end...

Continue Reading
Imperative Logistics Group Enhances Next-Flight-Out Services

Updated Category News Views 327

Imperative Logistics Group Expands with DTH Expeditors Imperative Logistics Group has recently made a strategic move by acquiring DTH Expeditors, Inc., a prominent provider in high-touch domestic expedited services. This acquisition significantly enhances Imperative's capabilities in the next-flight-out (NFO) logistics sector, which is increasingly vital in today’s...

Continue Reading
Protecting Your Rights as a Five Below, Inc. Shareholder

Updated Category News Views 95

Understanding Your Rights as a Five Below, Inc. Shareholder As a shareholder, it’s crucial to understand your rights in the corporate landscape. Five Below, Inc. (NASDAQ: FIVE) is a well-known company, and being a shareholder means you have a stake in the success and governance of the organization. If you have been investing in its stocks for a significant period,...

Continue Reading
Jefferies Rates Endesa Shares As Hold with Price Target Insights

Updated Category News Views 53

Jefferies Initiates Coverage on Endesa with a Hold Rating Endesa, S.A. (ELE:SM) (OTC: ELEZY) recently came under the spotlight as Jefferies offered new coverage on the stock, assigning it a Hold rating. The analysts set a price target of EUR21.00, a value derived from the company's financial health and the evolving regulatory landscape in Spain. Jefferies emphasized that...

Continue Reading